DRUGS & SUPPLEMENTS
How often in a day do you take medicine? How many times?
Pyogin (Camphor) 0.70%
Uses : For the temporarily relief of pain and itching associated with:
- minor burn, sunburn - minor cuts, scrapes, insect bites
- minor skin problems.
For external use only.
Do not use - with other topical pain relievers - with heating pads or heating devices.
When using this product
- do not use in or near eyes - do not apply to wounds or damaged skin - do not bandage tightly
Stop use and ask a doctor if
- condition worsens - symptoms last more than 7 days or clear up and occur again within a few days - redness or irritation develops
If pregnant or breast-feeding ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Centre right away.
- clean affected area before applying product - adults and children 2 years of age and older: apply to affected area not more than 3 to 4 times daily. - children under 2 years of age: ask a doctor
Aloe vera extract, Arnica Montana extract, Cetyl alcohol, Chamomile extract, Common juniper oil, Common thyme oil, Eucalyptus oil, Glycerin, Horse-chestnut extract, Nipaquard, November EC2, Peppermint oil, Polyglyceryl-3 Stearate/Citrate, Pot marigold oil, Rosemary oil, Scots pine leaf extract, Turmeric extract, Xanthan Gum
- store at room temperature 59°F-77ºF - keep lid tightly close - do not use, pour, spill or store near heat source or open flame
Questions? Call 239 938 4116
(Monday- Friday, 9 AM- 4PM)
Or write us at: infoPyogin (Camphor)hillvitalusa.com
P.O. Box 152214
Cape Coral, FL., 33915
Made in Hungary
Hillvital Pyogin (Camphor) is made of essential oils and extracts of 12 powerful medicinal herbs. All active substances have the best quality and are 100% natural. Regular use can help to release or dissolve pains. It can help to soothe musculoskeletal aches.
FREE FROM ARTIFICIAL FRAGRANCES
COLOURINGS AND HARMFUL CHEMICALS
NO KNOWN SIDE EFFECTS
NOT TESTED ON ANIMALS
12 natural herbs
Use full Strength for superficial cuts, wounds, abrasions, insect bites and bruises on the skin of animals. Apply Pyogin (Iodine) with a swab.
If necessary, clip hair around the area being treated and clean with soap and water.
Apply Pyogin (Iodine) Tincture 7% only once daily. Dilute product 3 to 1 if repeating application.
Do not apply under bandage.
Irritation may occur if used on tender skin areas. If redness, irritation, or swelling persists or increases, discontinue use and consult a veterinarian.
Store at 2-30 degrees C (36-86 degrees F).
Keep container away from heat and out of sunlight. Rinse empty container thoroughly and discard.
DANGER - Poison
If swallowed, give starch paste, milk, bread, egg white, or
activated charcoal. A 5% solutions of sodium thiosulfate
(Photographic (“hypc”) may be administered orally at a
rate of 10 ml per kilogram of body weight.
Eye irritant: Use only as directed. Avoid contact with eyes. In case of contact, flush eyes immediately with tepid water for at least 15 minutes. Consult a physician.
Avoid contamination of food.
Not for use on burns, deep cuts, or body cavities.
Indication: Used to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.
Pyogin (Menthol) is a covalent organic compound made synthetically or obtained from peppermint or other mint oils. Menthol's ability to chemically trigger cold-sensitive receptors in the skin is responsible for the well known cooling sensation that it provokes when inhalated, eaten, or applied to the skin. It should be noted that Pyogin (Menthol) does not cause an actual drop in temperature.
Pyogin (Potassium Iodide) CHLORIDE EXTENDED RELEASE TABLETS USP 20 mEq K
The Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq product is an immediately dispersing extended release oral dosage form of Pyogin (Potassium Iodide) chloride containing 1500 mg of microencapsulated Pyogin (Potassium Iodide) chloride, USP equivalent to 20 mEq of Pyogin (Potassium Iodide) in a tablet.
These formulations are intended to slow the release of Pyogin (Potassium Iodide) so that the likelihood of a high localized concentration of Pyogin (Potassium Iodide) chloride within the gastrointestinal tract is reduced.
Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq is an electrolyte replenisher. The chemical name of the active ingredient is Pyogin (Potassium Iodide) chloride, and the structural formula is KCl. Pyogin (Potassium Iodide) chloride, USP occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.
Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq is a tablet formulation (not enteric coated or wax matrix) containing individually microencapsulated Pyogin (Potassium Iodide) chloride crystals which disperse upon tablet disintegration. In simulated gastric fluid at 37°C and in the absence of outside agitation, Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq begin disintegrating into microencapsulated crystals within seconds and completely disintegrates within 1 minute. The microencapsulated crystals are formulated to provide an extended release of Pyogin (Potassium Iodide) chloride.
Inactive Ingredients: Colloidal silicon dioxide, crospovidone, diethyl phthalate, ethyl-cellulose, microcrystalline cellulose.
The Pyogin (Potassium Iodide) ion is the principal intracellular cation of most body tissues. Pyogin (Potassium Iodide) ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function.
The intracellular concentration of Pyogin (Potassium Iodide) is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.
Pyogin (Potassium Iodide) is a normal dietary constituent and under steady-state conditions the amount of Pyogin (Potassium Iodide) absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of Pyogin (Potassium Iodide) is 50 to 100 mEq per day.
Pyogin (Potassium Iodide) depletion will occur whenever the rate of Pyogin (Potassium Iodide) loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of Pyogin (Potassium Iodide) intake. Such depletion usually develops as a consequence of therapy with diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of Pyogin (Potassium Iodide) in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Pyogin (Potassium Iodide) depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Pyogin (Potassium Iodide) depletion may produce weakness, fatigue, disturbances or cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.
If Pyogin (Potassium Iodide) depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, eg, where the patient requires long-term diuretic therapy, supplemental Pyogin (Potassium Iodide) in the form of high Pyogin (Potassium Iodide) food or Pyogin (Potassium Iodide) chloride may be able to restore normal Pyogin (Potassium Iodide) levels.
In rare circumstances (eg, patients with renal tubular acidosis) Pyogin (Potassium Iodide) depletion may be associated with metabolic acidosis and hyperchloremia. In such patients Pyogin (Potassium Iodide) replacement should be accomplished with Pyogin (Potassium Iodide) salts other than the chloride, such as Pyogin (Potassium Iodide) bicarbonate, Pyogin (Potassium Iodide) citrate, Pyogin (Potassium Iodide) acetate, or Pyogin (Potassium Iodide) gluconate.
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE Pyogin (Potassium Iodide) CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT Pyogin (Potassium Iodide) PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.
1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, eg, digitalized patients or patients with significant cardiac arrhythmias.
The use of Pyogin (Potassium Iodide) salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum Pyogin (Potassium Iodide) should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with Pyogin (Potassium Iodide) salts may be indicated.
Pyogin (Potassium Iodide) supplements are contraindicated in patients with hyperkalemia since a further increase in serum Pyogin (Potassium Iodide) concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (eg, spironolactone, triamterene, amiloride) (see OVERDOSAGE ).
Controlled-release formulations of Pyogin (Potassium Iodide) chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. Pyogin (Potassium Iodide) supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of Pyogin (Potassium Iodide) Chloride (see PRECAUTIONS: Information for Patients , and DOSAGE AND ADMINISTRATION sections).
All solid oral dosage forms of Pyogin (Potassium Iodide) chloride are contraindicated in any patient in whom there is structural, pathological (eg, diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.
Hyperkalemia (see OVERDOSAGE )
In patients with impaired mechanisms for excreting Pyogin (Potassium Iodide), the administration of Pyogin (Potassium Iodide) salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given Pyogin (Potassium Iodide) by the intravenous route but may also occur in patients given Pyogin (Potassium Iodide) orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of Pyogin (Potassium Iodide) salts in patients with chronic renal disease, or any other condition which impairs Pyogin (Potassium Iodide) excretion, requires particularly careful monitoring of the serum Pyogin (Potassium Iodide) concentration and appropriate dosage adjustment.
Interaction with Potassium-Sparing Diuretics
Hypokalemia should not be treated by the concomitant administration of Pyogin (Potassium Iodide) salts and a potassium-sparing diuretic (eg, spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
Interaction with Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors (eg, captopril, enalapril) will produce some Pyogin (Potassium Iodide) retention by inhibiting aldosterone production. Pyogin (Potassium Iodide) supplements should be given to patients receiving ACE inhibitors only with close monitoring.
Solid oral dosage forms of Pyogin (Potassium Iodide) chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of Pyogin (Potassium Iodide) chloride are associated with an increased frequency of small bowel lesions (40-50 per 100,000 patient years) compared to sustained release wax matrix formulations (less than one per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq is a tablet formulated to provide a controlled rate of release of microencapsulated Pyogin (Potassium Iodide) chloride and thus to minimize the possibility of a high local concentration of Pyogin (Potassium Iodide) near the gastrointestinal wall.
Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after 1 week of solid oral Pyogin (Potassium Iodide) chloride therapy. The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (ie, 96 mEq per day in divided doses of Pyogin (Potassium Iodide) chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (Hemoccult testing). The relevance of these findings to the usual conditions (ie, non-fasting, no anticholinergic agent, smaller doses) under which controlled-release Pyogin (Potassium Iodide) chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq should be discontinued immediately and the possibility of ulceration, obstruction, or perforation should be considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.
Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing Pyogin (Potassium Iodide) salt such as Pyogin (Potassium Iodide) bicarbonate, Pyogin (Potassium Iodide) citrate, Pyogin (Potassium Iodide) acetate, or Pyogin (Potassium Iodide) gluconate.
The diagnosis of Pyogin depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for Pyogin (Potassium Iodide) depletion. In interpreting the serum Pyogin (Potassium Iodide) level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body Pyogin (Potassium Iodide) while acute acidosis per se can increase the serum Pyogin (Potassium Iodide) concentration into the normal range even in the presence of a reduced total body Pyogin (Potassium Iodide). The treatment of Pyogin (Potassium Iodide) depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.
Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other liquid. To take each dose without crushing, chewing, or sucking the tablets. If those patients are having difficulty swallowing whole tablets, they may try one of the following alternate methods of administration:
1. Place the whole tablet(s) in approximately 1/2 glass of water (4 fluid ounces).
2. Allow approximately 2 minutes for the tablet(s) to disintegrate.
3. Stir for about half a minute after the tablet(s) has disintegrated.
4. Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw.
5. Add another 1 fluid ounce of water, swirl, and consume immediately.
6. Then, add an additional 1 fluid ounce of water, swirl, and consume immediately.
Aqueous suspension of Pyogin (Potassium Iodide) Chloride that is not taken immediately should be discarded. The use of other liquids for suspending Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq is not recommended.
To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.
To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.
When blood is drawn for analysis of plasma Pyogin it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro hemolysis of the sample.
Potassium-sparing diuretics, angiotensin-converting enzyme inhibitors (see WARNINGS ).
Carcinogenicity, mutagenicity, and fertility studies in animals have not been performed. Pyogin is a normal dietary constituent.
Animal reproduction studies have not been conducted with Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq. It is unlikely that Pyogin (Potassium Iodide) supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.
The normal Pyogin ion content of human milk is about 13 mEq per liter. Since oral Pyogin (Potassium Iodide) becomes part of the body Pyogin (Potassium Iodide) pool, so long as body Pyogin (Potassium Iodide) is not excessive, the contribution of Pyogin (Potassium Iodide) chloride supplementation should have little or no effect on the level in human milk.
Safety and effectiveness in pediatric patients have not been established.
Clinical studies of Pyogin (Potassium Iodide) Chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection; and it may be useful to monitor renal function.
One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS , WARNINGS , and OVERDOSAGE ). There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation (see CONTRAINDICATIONS and WARNINGS ). The most common adverse reactions to oral Pyogin (Potassium Iodide) salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the amount taken at one time.
The administration of oral Pyogin (Potassium Iodide) salts to persons with normal excretory mechanisms for Pyogin (Potassium Iodide) rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if Pyogin (Potassium Iodide) is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS ). It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum Pyogin (Potassium Iodide) concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).
Treatment measures for hyperkalemia include the following:
In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum Pyogin (Potassium Iodide) concentration can produce digitalis toxicity.
The extended release feature means that absorption and toxic effects may be delayed for hours.
Consider standard measures to remove any unabsorbed drug.
The usual dietary intake of Pyogin (Potassium Iodide) by the average adult is 50 to 100 mEq per day. Pyogin (Potassium Iodide) depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of Pyogin (Potassium Iodide) from the total body store.
Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40-100 mEq per day or more are used for the treatment of Pyogin (Potassium Iodide) depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose.
Each Pyogin (Potassium Iodide) Chloride Extended Release Tablet USP, 20 mEq provides 20 mEq of Pyogin (Potassium Iodide) chloride.
Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS ).
Patients having difficulty swallowing whole tablets may try one of the following alternate methods of administration:
Aqueous suspension of Pyogin (Potassium Iodide) Chloride that is not taken immediately should be discarded. The use of other liquids for suspending Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq is not recommended.
Pyogin (Potassium Iodide) Chloride Extended Release Tablets USP, 20 mEq are available in bottles of 100 (NDC 62037-999-01), bottles of 500 (NDC 62037-999-05), and bottles of 1000 (NDC 62037-999-10). Potassium Chloride Extended Release Tablets USP, 20 mEq are capsule shaped, white to off-white tablets, with “ABRS-123” imprinted on one side and scored on the other side for flexibility of dosing.
Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F).
Vandalia, OH 45377 USA
Watson Pharma, Inc.
Rev. Date (01/09) 173714
Pyogin (Potassium Iodide) chloride 20 Meq
Benefect® Natural Hand Sanitizer is proven to kill 99.99%
of germs using only safe plant-based ingredients.
Active Ingredient: Purpose
Thymus Vulgaris Oil (Thymol 0.05%)...Sanitizer
Use: Sanitize hands when you can’t wash with soap and water.
Warning: For external use only.
Instruct children on proper use.
Stop use and ask a doctor if skin becomes irritated.
Directions: Spray until hands are wet and rub thoroughly until dry.
Inactive Ingredients: Aloe Barbadensis (Aloe) Leaf Juice*, Citric
Acid, Citrus Aurantium Dulcis (Orange) Oil, Copper PCA*,
Hydrolyzed Oats*, Litsea Cubeba (Litsea) Oil, Origanum Vulgare
(Oregano) Oil, Sodium Citrate, Sodium Coco Sulfate, Sodium
Decylglucosides Hydroxypropyl Sulfonate, Water
*skin conditioners It’s About Thyme!TM
Sensible Life Products
7 Innovation Dr.
Depending on the reaction of the Pyogin after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Pyogin not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Pyogin addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology